STOCK TITAN

[Form 4] Addus HomeCare Corp. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Esteban Lopez, a director of Addus HomeCare (ADUS), sold 522 shares of common stock on 08/08/2025 at $109 per share. After the sale he beneficially owns 4,016 shares held directly. The filing reports only this non-derivative sale, shows no derivative holdings, and does not disclose a 10b5-1 trading plan. The Form 4 was executed by an attorney-in-fact.

Esteban Lopez, direttore di Addus HomeCare (ADUS), ha venduto 522 azioni ordinarie l'08/08/2025 a 109 $ per azione. Dopo la vendita ne detiene beneficiariamente 4,016 azioni detenute direttamente. La comunicazione riporta soltanto questa vendita non derivata, non indica posizioni in strumenti derivati e non dichiara un piano di trading 10b5-1. Il Form 4 è stato sottoscritto da un procuratore.

Esteban Lopez, director de Addus HomeCare (ADUS), vendió 522 acciones ordinarias el 08/08/2025 a 109 $ por acción. Tras la venta posee beneficiariamente 4,016 acciones en propiedad directa. La presentación solo informa de esta venta no derivada, no muestra participaciones en derivados y no revela un plan de negociación 10b5-1. El Form 4 fue firmado por un apoderado.

Addus HomeCare(ADUS)의 이사 Esteban Lopez는 08/08/2025에 보통주 522주를 주당 109달러에 매각했습니다. 매각 후 그는 직접 보유하는 4,016주를 실질적으로 소유하고 있습니다. 제출 서류에는 이 비파생 매도만 보고되어 있으며 파생상품 보유는 없고 10b5-1 거래계획도 공개되지 않았습니다. Form 4는 대리인에 의해 작성되었습니다.

Esteban Lopez, administrateur d'Addus HomeCare (ADUS), a vendu 522 actions ordinaires le 08/08/2025 au prix de 109 $ par action. Après la vente, il détient à titre bénéficiaire 4,016 actions détenues directement. Le dépôt n'enregistre que cette vente non dérivée, n'indique aucune position en dérivés et ne divulgue pas de plan de négociation 10b5-1. Le Form 4 a été signé par un mandataire.

Esteban Lopez, Direktor von Addus HomeCare (ADUS), verkaufte am 08/08/2025 522 Stammaktien zum Preis von 109 $ pro Aktie. Nach dem Verkauf besitzt er wirtschaftlich 4,016 Aktien, die direkt gehalten werden. Die Meldung berichtet nur über diesen nicht-derivativen Verkauf, weist keine Derivatbestände aus und legt keinen 10b5-1-Handelsplan offen. Das Form 4 wurde von einem Bevollmächtigten ausgeführt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: A single small director sale: 522 shares at $109, leaving 4,016 shares directly owned—routine disclosure with limited market impact.

The transaction is a straightforward non-derivative sale reported on Form 4. The sale size (522 shares) and remaining direct holding (4,016 shares) are explicitly stated. No derivative positions or 10b5-1 plan are disclosed, which limits interpretive hooks for trading intent. From an investor-materiality perspective this appears routine rather than transformational for ADUS.

TL;DR: Director-level sale properly reported; disclosure shows direct ownership and an attorney-in-fact signature, consistent with standard compliance practices.

The Form 4 documents required insider reporting: the reporting person is identified as a director and the transaction is recorded as a sale of common stock. The presence of an attorney-in-fact signature indicates the filing was executed by a designated agent. The absence of derivative entries and no indicated 10b5-1 plan are noted. Governance-wise, this filing meets routine disclosure expectations and raises no immediate procedural concerns.

Esteban Lopez, direttore di Addus HomeCare (ADUS), ha venduto 522 azioni ordinarie l'08/08/2025 a 109 $ per azione. Dopo la vendita ne detiene beneficiariamente 4,016 azioni detenute direttamente. La comunicazione riporta soltanto questa vendita non derivata, non indica posizioni in strumenti derivati e non dichiara un piano di trading 10b5-1. Il Form 4 è stato sottoscritto da un procuratore.

Esteban Lopez, director de Addus HomeCare (ADUS), vendió 522 acciones ordinarias el 08/08/2025 a 109 $ por acción. Tras la venta posee beneficiariamente 4,016 acciones en propiedad directa. La presentación solo informa de esta venta no derivada, no muestra participaciones en derivados y no revela un plan de negociación 10b5-1. El Form 4 fue firmado por un apoderado.

Addus HomeCare(ADUS)의 이사 Esteban Lopez는 08/08/2025에 보통주 522주를 주당 109달러에 매각했습니다. 매각 후 그는 직접 보유하는 4,016주를 실질적으로 소유하고 있습니다. 제출 서류에는 이 비파생 매도만 보고되어 있으며 파생상품 보유는 없고 10b5-1 거래계획도 공개되지 않았습니다. Form 4는 대리인에 의해 작성되었습니다.

Esteban Lopez, administrateur d'Addus HomeCare (ADUS), a vendu 522 actions ordinaires le 08/08/2025 au prix de 109 $ par action. Après la vente, il détient à titre bénéficiaire 4,016 actions détenues directement. Le dépôt n'enregistre que cette vente non dérivée, n'indique aucune position en dérivés et ne divulgue pas de plan de négociation 10b5-1. Le Form 4 a été signé par un mandataire.

Esteban Lopez, Direktor von Addus HomeCare (ADUS), verkaufte am 08/08/2025 522 Stammaktien zum Preis von 109 $ pro Aktie. Nach dem Verkauf besitzt er wirtschaftlich 4,016 Aktien, die direkt gehalten werden. Die Meldung berichtet nur über diesen nicht-derivativen Verkauf, weist keine Derivatbestände aus und legt keinen 10b5-1-Handelsplan offen. Das Form 4 wurde von einem Bevollmächtigten ausgeführt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lopez Esteban

(Last) (First) (Middle)
6303 COWBOYS WAY
SUITE 600

(Street)
FRISCO TX 75034

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Addus HomeCare Corp [ ADUS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/08/2025 S 522 D $109 4,016 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Brian Poff, Attorney-In-Fact for Esteban Lopez 08/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Esteban Lopez report on the ADUS Form 4?

He reported a sale of 522 shares of Addus HomeCare common stock on 08/08/2025 at $109 per share.

How many shares does Esteban Lopez beneficially own after the reported transaction?

He beneficially owns 4,016 shares following the reported sale, held directly.

Was any derivative security reported for Esteban Lopez in this Form 4?

No derivative securities are listed; Table II contains no derivative transactions or holdings.

What is the reporting person's relationship to Addus HomeCare (ADUS)?

The form identifies Esteban Lopez as a director of the issuer.

Who signed the Form 4 for Esteban Lopez?

The Form 4 is executed by Brian Poff as attorney-in-fact for Esteban Lopez.
Addus Homecare Corp

NASDAQ:ADUS

ADUS Rankings

ADUS Latest News

ADUS Latest SEC Filings

ADUS Stock Data

2.12B
17.93M
2.58%
102.82%
3.69%
Medical Care Facilities
Services-home Health Care Services
Link
United States
FRISCO